News
HealthDay on MSN23h
First drug to treat bronchiectasis lung condition approved by FDA
The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...
Stocktwits on MSN21h
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...
A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...
The Clean Label Project tested store-bought coffee and found it is mostly free of harmful levels of toxins and contaminants, ...
Asianet Newsable on MSN19h
Apple Plans Tabletop Robot, Among Other AI Products, Says Report
The tabletop robot, resembling an iPad mounted on a movable limb that can follow users in a room, is targeted for 2027, ...
Insmed Inc. stock grades by Barron's. View INSM fundamental and sentiment analysis powered by MarketGrader.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback